Aurigene to Present its CDK7, Dual PD-1/VISTA and IRAK4 Inhibitor Programs at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (November 5-9, Boston, MA)

Nov 03, 2015, 06:00 ET from Aurigene Discovery

BOSTON, November 3, 2015 /PRNewswire/ --

Aurigene will present data on its potent and selective CDK7 novel covalent inhibitor program, which is currently in Lead Optimization.

     (Logo: http://photos.prnewswire.com/prnh/20130418/608115 )

Aurigene and its partner Curis, Inc. (NASDAQ: CRIS) will be presenting data at the poster sessions from two programs at the AACR-NCI-EORTC International Conference.

Aurigene and Curis will present data on:

(A) First-in-class orally available PD-L1/VISTA antagonists for cancer therapy

(B) interleukin-1 receptor association kinase-4 (IRAK-4) inhibitor  

Additional information on the presentations can be found below and abstracts can be accessed at www.aacr.org.  

Poster Presentations  

First-in-class orally available immune checkpoint antagonists: PD-L1/VISTA  

Title: First-in-class orally available immune checkpoint antagonists for cancer therapy  

Session ID:               Poster Session A

Session Title:            Immune Modulators

Session Date and Time:     Friday Nov 6, 2015 12:15 PM - 3:15 PM

Location:                 Exhibit Hall C-D

Permanent Abstract Number: A96

Selective CDK7 Covalent Inhibitors  

Title: Potent and selective inhibition of CDK7 by novel covalent inhibitors Session Category: Experimental and Molecular Therapeutics  

Session ID:                Poster Session C

Session Title:             Therapeutic Agents: Small Molecule Kinase Inhibitors

Session Date and Time:     Sunday Nov 8, 2015 12:30 PM - 3:30 PM

Location:                  Exhibit Hall C-D

Permanent Abstract Number: C190

Novel, selective IRAK4 Inhibitors for Oncology  

Title: Efficacy of novel IRAK4 inhibitors in ABC-DLBCL and AML models   

Session ID:                Poster Session C

Session Title:             Therapeutic Agents: Small Molecule Kinase Inhibitors

Session Date and Time:     Sunday Nov 8, 2015 12:30 PM - 3:30 PM

Location:                 Exhibit Hall C-D

Permanent Abstract Number: C191

About Aurigene:  

Aurigene is a specialized, discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene's Programmed Death pathway program is the first of several immune checkpoint programs that are at different stages of discovery and preclinical development. Aurigene has signed four licensing deals in the last couple of years. Aurigene is currently seeking partners for its current pipeline of advanced assets (a) RORg for autoimmune diseases which is in preclinical development (b) Novel NAMPT inhibitors for niche cancers, also in preclinical development (c) Covalent CDK7 and KRAS small molecule programs that are currently in lead optimization. For more information about Aurigene and our pipeline, please visit Aurigene's website at http://aurigene.com/.

Media Contact: Rajshree KT Director Corporate Development & Strategy +91-40-4465 7777 pr@aurigene.com 

SOURCE Aurigene Discovery